GlaxoSmithKline has an active research and development programme targeted at both seasonal and pandemic influenza and has recently committed over one billion pounds ($NZ2.96 billion) to expand capacity for manufacturing flu vaccine and its anti-viral influenza treatment Relenza® (zanamivir for inhalation).
http://www.scoop.co.nz/stories/SC0605/S00079.htm
Maybe this is why???
why the jump today.., page-5
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)